Pharmacology & Therapeutics presents lucid, critical and authoritative reviews of currently important topics in pharmacology. Since articles are commissioned, instructions to authors are provided by the editor responsible for recruiting the work. Celebrating its 20th year of scientific excellence, Pharmacology & Therapeutics continues to be among the top 10 most cited journals in pharmacology.
药理学和治疗学提出了清晰的，关键的和权威的审查目前重要的主题药理学。由于文章是委托撰写的，所以由负责招聘工作的编辑向作者提供说明。庆祝其20年的科学卓越，药理学与治疗学继续在前10名最引用的药理学期刊。
Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2018.09.007
The neuropsychopharmacology of cannabis: A review of human imaging studies
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2018.10.006
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2018.11.010
RNA therapy: Are we using the right molecules?
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2018.11.011
Antifungal drugs: New insights in research & development.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2018.10.008
Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2018.10.009
Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.02.017
Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2019.01.002
CD26/DPP4 - a potential biomarker and target for cancer therapy.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.02.015
Biochemical and physiological importance of the CYP26 retinoic acid hydroxylases.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107400
P53 in kidney injury and repair: Mechanism and therapeutic potentials
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2018.10.013
Drugging K-RasG12C through covalent inhibitors: Mission possible?
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.06.007
Intestinal microbiome as a novel therapeutic target for local and systemic inflammation.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.03.006
Drug resistance in non-small cell lung Cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.06.005
Prostaglandins in asthma and allergic diseases☆
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2018.08.001
Acute kidney injury overview: From basic findings to new prevention and therapy strategies.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.04.001
The origin of NMDA receptor hypofunction in schizophrenia.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107426
Lactate/GPR81 signaling and proton motive force in cancer: Role in angiogenesis, immune escape, nutrition, and Warburg phenomenon.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107451
Super-enhancers in cancer.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.02.014
Lorcaserin: a review of its preclinical and clinical pharmacology and therapeutic potential.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107417
Immune mechanisms mediating abscopal effects in radioimmunotherapy
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2018.12.002
Stress responses in stromal cells and tumor homeostasis.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.04.004
Autophagy as a novel therapeutic target in vascular calcification.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107430
Molecular mechanisms of cereblon-based drugs.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.06.004
Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107395
Modulating Wnt signaling at the root: Porcupine and Wnt acylation.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.02.009
Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2018.08.012
Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2019.02.013
Epigenome modifiers and metabolic rewiring: New frontiers in therapeutics
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2018.08.008
Vascular Disrupting Agents in cancer treatment: Cardiovascular toxicity and implications for co-administration with other cancer chemotherapeutics.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.06.001
Cognitive dysfunction in major depression: From assessment to novel therapies.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.05.013
Mast cell tryptase - Marker and maker of cardiovascular diseases.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.03.008
Fighting against depression with TREK‐1 blockers: Past and future. A focus on spadin
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2018.10.003
Clioquinol: To harm or heal.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.03.009
The eye as a novel imaging site in diabetes research
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2019.01.005
The UGTome: the expanding diversity of UDP glycosyltransferases and its impact on small molecule metabolism.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107414
Use of glucocorticoids in the critical care setting: science and clinical evidence.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107428
Regulation of the phosphoprotein phosphatase 2A system and its modulation during oxidative stress: A potential therapeutic target?
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.02.011
Environmental exposures, stem cells, and cancer.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107398
Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107397
Therapeutic strategy for atherosclerosis based on bone-vascular axis hypothesis.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107436
Non‐vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: Differences between factor IIa and factor Xa inhibition?
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2018.10.005
Quenching the fires: Pro‐resolving mediators, air pollution, and smoking
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2019.02.001
Modulation of retinoid signaling: therapeutic opportunities in organ fibrosis and repair.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107415
Isolevuglandins as mediators of disease and the development of dicarbonyl scavengers as pharmaceutical interventions.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107418
Limiting tumor seeding as a therapeutic approach for metastatic disease.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.03.007
Are cell‐based therapies for kidney disease safe? A systematic review of preclinical evidence
来源期刊：Pharmacology & TherapeuticsDOI：10.1016/j.pharmthera.2019.01.004
Role of Neutrophils in Ischemic Heart Failure.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107424
Unraveling cancer lineage drivers in squamous cell carcinomas.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.107448
Sarcolemmal α2-adrenoceptors in feedback control of myocardial response to sympathetic challenge.
来源期刊：Pharmacology & therapeuticsDOI：10.1016/j.pharmthera.2019.01.007
